"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 4 | 7 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 1 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 6 | 1 | 7 |
| 2019 | 5 | 2 | 7 |
| 2020 | 11 | 5 | 16 |
| 2021 | 13 | 6 | 19 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 0 | 9 |
| 2024 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed. J Acquir Immune Defic Syndr. 2024 07 01; 96(3):280-289.
-
Psychiatry and Family Medicine Residents' Likelihood of Prescribing HIV Pre-exposure Prophylaxis to Patients With Mental Illness and HIV Vulnerability. J Acquir Immune Defic Syndr. 2024 07 01; 96(3):231-240.
-
Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. J Int AIDS Soc. 2024 Jul; 27 Suppl 3:e26319.
-
Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States. AIDS Behav. 2024 Jul; 28(7):2226-2238.
-
"There hasn't been a push to identify patients in the emergency department"-Staff perspectives on automated identification of candidates for pre-exposure prophylaxis (PrEP): A qualitative study. PLoS One. 2024; 19(3):e0300540.
-
Assessing Patient Acceptance of an Automated Algorithm to Identify Ciswomen for HIV Pre-Exposure Prophylaxis. J Womens Health (Larchmt). 2024 Apr; 33(4):505-514.
-
Increasing providers' PrEP prescription for Black cisgender women: A qualitative study to improve provider knowledge and competency via PrEP training. Womens Health (Lond). 2024 Jan-Dec; 20:17455057241277974.
-
Low daily oral PrEP adherence and low validity of self-report in a randomized trial among PWID in Ukraine. Int J Drug Policy. 2024 Jan; 123:104284.
-
Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender Women. AIDS Patient Care STDS. 2023 12; 37(12):574-582.
-
Evaluation of multiple data sources for predicting increased need for HIV prevention among cisgender women: understanding missed opportunities for Pre-exposure Prophylaxis (PrEP). BMC Infect Dis. 2023 Nov 09; 23(1):781.